BiomX | Phage therapy

Customized phage therapies to eradicate
harmful bacteria in chronic diseases

Our phage therapy development and target discovery technologies were developed by world-leading scientists from top-tier institutions including MIT and the Weizmann Institute of Science
Learn about our technology

BiomX’s founders, management and investors all have a long history of excellence that is propelling us to continued success and innovation
Learn about our leadership team

Featured Highlights

To View Our Corporate Presentation, click here.

May, 2020

BiomX Key Opinion Leader Symposium on BX001 for Acne

December 15, 2019

BiomX News

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Nov 16, 2020

– Presentation featured at The Liver Meeting® 2020, the AASLD Annual Meeting, details support for the design of phage therapy candidate BX003 –

BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates

Nov 12, 2020

BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates

BiomX to Present at Upcoming November Investor Conferences

Nov 11, 2020

BiomX to Present at Upcoming November Investor Conferences
Click the link for webcasting details

Read More

OUR INVESTORS